

ICMJE DISCLOSURE FORM

Date: 2023.2.22
Your Name: Na Wang
Manuscript Title: RNA-binding protein ENO1 promotes the glycolysis and tumor progression of gastric cancer by binding to and regulating gastric cancer-related genes
Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by: (I) Project name: Mechanism and targeted therapy of ENO1 promoting aerobic glycolysis of gastric cancer cells by regulating PI3K/AKT/mTOR/PKM2 pathway (Grant No. 2019-0203-SFC-0015; Category: Gansu Provincial Key Research and Development Project-Social Development Category; Source: Gansu Provincial Science and Technology Department).	

		<p>(II) Project name: Mechanism of activating PKM2 through VEGF ENO1/PI3K/AKT pathway to promote aerobic glycolysis of gastric cancer cells (grant No. ZX-62000002-2021-139; Category: The Hospital Fund of Lanzhou University First Hospital; Source: Lanzhou University First Hospital). (III) The mechanism of ENO1 regulating aerobic glycolysis through PI3K/AKT/c-Fos pathway to promote the proliferation and metastasis of gastric cancer (Grant No. 20JR10RA672; Category: Gansu Science and Technology Project; Source: Gansu Provincial Science and Technology Department). (IV) Project name: Effect of ENO1 on the proliferation and metastasis of gastric cancer and its molecular mechanism (Grant No. 2020-25; Category: Young Scientific and Technological Talents Promotion Project in 2020 from Gansu Association for Science and Technology; Source: Gansu Province Science and Technology Association).</p>	
--	--	--	--

Time frame: past 36 months

2	Grants or contracts from any entity (if not indicated in item #1 above).	___ None	
3	Royalties or licenses	___ None	
4	Consulting fees	___ None	
5	Payment or honoraria for	___ None	

	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

This work was supported by: (I) Project name: Mechanism and targeted therapy of ENO1 promoting aerobic glycolysis of gastric cancer cells by regulating PI3K/AKT/mTOR/PKM2 pathway (Grant No. 2019-0203-SFC-0015; Category: Gansu Provincial Key Research and Development Project-Social Development Category; Source: Gansu Provincial Science and Technology Department). (II) Project name: Mechanism of activating PKM2 through VEGF ENO1/PI3K/AKT pathway to promote aerobic glycolysis of gastric cancer cells (grant No. ZX-62000002-2021-139; Category: The Hospital Fund of Lanzhou University First Hospital; Source: Lanzhou University First Hospital). (III) The mechanism of ENO1 regulating aerobic glycolysis through PI3K/AKT/c-Fos pathway to promote the proliferation and metastasis of gastric cancer (Grant No. 20JR10RA672; Category: Gansu Science and Technology Project; Source: Gansu Provincial Science and Technology Department). (IV) Project name: Effect of ENO1 on the proliferation and metastasis of gastric cancer and its molecular mechanism (Grant No. 2020-25; Category: Young Scientific and Technological Talents Promotion Project in 2020 from Gansu Association for Science and Technology; Source: Gansu Province Science and Technology Association). I have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 2023.2.22
Your Name: Hui Qiao
Manuscript Title: RNA-binding protein ENO1 promotes the glycolysis and tumor progression of gastric cancer by binding to and regulating gastric cancer-related genes
Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by: (I) Project name: Mechanism and targeted therapy of ENO1 promoting aerobic glycolysis of gastric cancer cells by regulating PI3K/AKT/mTOR/PKM2 pathway (Grant No. 2019-0203-SFC-0015; Category: Gansu Provincial Key Research and Development Project-Social Development Category; Source: Gansu Provincial Science and Technology Department).	

		<p>(II) Project name: Mechanism of activating PKM2 through VEGF ENO1/PI3K/AKT pathway to promote aerobic glycolysis of gastric cancer cells (grant No. ZX-62000002-2021-139; Category: The Hospital Fund of Lanzhou University First Hospital; Source: Lanzhou University First Hospital). (III) The mechanism of ENO1 regulating aerobic glycolysis through PI3K/AKT/c-Fos pathway to promote the proliferation and metastasis of gastric cancer (Grant No. 20JR10RA672; Category: Gansu Science and Technology Project; Source: Gansu Provincial Science and Technology Department). (IV) Project name: Effect of ENO1 on the proliferation and metastasis of gastric cancer and its molecular mechanism (Grant No. 2020-25; Category: Young Scientific and Technological Talents Promotion Project in 2020 from Gansu Association for Science and Technology; Source: Gansu Province Science and Technology Association).</p>	
--	--	--	--

Time frame: past 36 months

2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	

	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

This work was supported by: (I) Project name: Mechanism and targeted therapy of ENO1 promoting aerobic glycolysis of gastric cancer cells by regulating PI3K/AKT/mTOR/PKM2 pathway (Grant No. 2019-0203-SFC-0015; Category: Gansu Provincial Key Research and Development Project-Social Development Category; Source: Gansu Provincial Science and Technology Department). (II) Project name: Mechanism of activating PKM2 through VEGF ENO1/PI3K/AKT pathway to promote aerobic glycolysis of gastric cancer cells (grant No. ZX-62000002-2021-139; Category: The Hospital Fund of Lanzhou University First Hospital; Source: Lanzhou University First Hospital). (III) The mechanism of ENO1 regulating aerobic glycolysis through PI3K/AKT/c-Fos pathway to promote the proliferation and metastasis of gastric cancer (Grant No. 20JR10RA672; Category: Gansu Science and Technology Project; Source: Gansu Provincial Science and Technology Department). (IV) Project name: Effect of ENO1 on the proliferation and metastasis of gastric cancer and its molecular mechanism (Grant No. 2020-25; Category: Young Scientific and Technological Talents Promotion Project in 2020 from Gansu Association for Science and Technology; Source: Gansu Province Science and Technology Association). I have no other conflicts of interest to declare.

Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 2023.2.22
Your Name: Jianpeng Hao
Manuscript Title: RNA-binding protein ENO1 promotes the glycolysis and tumor progression of gastric cancer by binding to and regulating gastric cancer-related genes
Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by: (I) Project name: Mechanism and targeted therapy of ENO1 promoting aerobic glycolysis of gastric cancer cells by regulating PI3K/AKT/mTOR/PKM2 pathway (Grant No. 2019-0203-SFC-0015; Category: Gansu Provincial Key Research and Development Project-Social Development Category; Source: Gansu Provincial Science and Technology Department).	

		<p>(II) Project name: Mechanism of activating PKM2 through VEGF ENO1/PI3K/AKT pathway to promote aerobic glycolysis of gastric cancer cells (grant No. ZX-62000002-2021-139; Category: The Hospital Fund of Lanzhou University First Hospital; Source: Lanzhou University First Hospital). (III) The mechanism of ENO1 regulating aerobic glycolysis through PI3K/AKT/c-Fos pathway to promote the proliferation and metastasis of gastric cancer (Grant No. 20JR10RA672; Category: Gansu Science and Technology Project; Source: Gansu Provincial Science and Technology Department). (IV) Project name: Effect of ENO1 on the proliferation and metastasis of gastric cancer and its molecular mechanism (Grant No. 2020-25; Category: Young Scientific and Technological Talents Promotion Project in 2020 from Gansu Association for Science and Technology; Source: Gansu Province Science and Technology Association).</p>	
--	--	--	--

Time frame: past 36 months

2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	

	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

This work was supported by: (I) Project name: Mechanism and targeted therapy of ENO1 promoting aerobic glycolysis of gastric cancer cells by regulating PI3K/AKT/mTOR/PKM2 pathway (Grant No. 2019-0203-SFC-0015; Category: Gansu Provincial Key Research and Development Project-Social Development Category; Source: Gansu Provincial Science and Technology Department). (II) Project name: Mechanism of activating PKM2 through VEGF ENO1/PI3K/AKT pathway to promote aerobic glycolysis of gastric cancer cells (grant No. ZX-62000002-2021-139; Category: The Hospital Fund of Lanzhou University First Hospital; Source: Lanzhou University First Hospital). (III) The mechanism of ENO1 regulating aerobic glycolysis through PI3K/AKT/c-Fos pathway to promote the proliferation and metastasis of gastric cancer (Grant No. 20JR10RA672; Category: Gansu Science and Technology Project; Source: Gansu Provincial Science and Technology Department). (IV) Project name: Effect of ENO1 on the proliferation and metastasis of gastric cancer and its molecular mechanism (Grant No. 2020-25; Category: Young Scientific and Technological Talents Promotion Project in 2020 from Gansu Association for Science and Technology; Source: Gansu Province Science and Technology Association). I have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 2023.2.22
Your Name: Chenghui Deng
Manuscript Title: RNA-binding protein ENO1 promotes the glycolysis and tumor progression of gastric cancer by binding to and regulating gastric cancer-related genes
Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by: (I) Project name: Mechanism and targeted therapy of ENO1 promoting aerobic glycolysis of gastric cancer cells by regulating PI3K/AKT/mTOR/PKM2 pathway (Grant No. 2019-0203-SFC-0015; Category: Gansu Provincial Key Research and Development Project-Social Development Category; Source: Gansu Provincial Science and Technology Department).	

		<p>(II) Project name: Mechanism of activating PKM2 through VEGF ENO1/PI3K/AKT pathway to promote aerobic glycolysis of gastric cancer cells (grant No. ZX-62000002-2021-139; Category: The Hospital Fund of Lanzhou University First Hospital; Source: Lanzhou University First Hospital). (III) The mechanism of ENO1 regulating aerobic glycolysis through PI3K/AKT/c-Fos pathway to promote the proliferation and metastasis of gastric cancer (Grant No. 20JR10RA672; Category: Gansu Science and Technology Project; Source: Gansu Provincial Science and Technology Department). (IV) Project name: Effect of ENO1 on the proliferation and metastasis of gastric cancer and its molecular mechanism (Grant No. 2020-25; Category: Young Scientific and Technological Talents Promotion Project in 2020 from Gansu Association for Science and Technology; Source: Gansu Province Science and Technology Association).</p>	
--	--	--	--

Time frame: past 36 months

2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	

	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

This work was supported by: (I) Project name: Mechanism and targeted therapy of ENO1 promoting aerobic glycolysis of gastric cancer cells by regulating PI3K/AKT/mTOR/PKM2 pathway (Grant No. 2019-0203-SFC-0015; Category: Gansu Provincial Key Research and Development Project-Social Development Category; Source: Gansu Provincial Science and Technology Department). (II) Project name: Mechanism of activating PKM2 through VEGF ENO1/PI3K/AKT pathway to promote aerobic glycolysis of gastric cancer cells (grant No. ZX-62000002-2021-139; Category: The Hospital Fund of Lanzhou University First Hospital; Source: Lanzhou University First Hospital). (III) The mechanism of ENO1 regulating aerobic glycolysis through PI3K/AKT/c-Fos pathway to promote the proliferation and metastasis of gastric cancer (Grant No. 20JR10RA672; Category: Gansu Science and Technology Project; Source: Gansu Provincial Science and Technology Department). (IV) Project name: Effect of ENO1 on the proliferation and metastasis of gastric cancer and its molecular mechanism (Grant No. 2020-25; Category: Young Scientific and Technological Talents Promotion Project in 2020 from Gansu Association for Science and Technology; Source: Gansu Province Science and Technology Association). I have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 2023.2.22
Your Name: Nan Zhou
Manuscript Title: RNA-binding protein ENO1 promotes the glycolysis and tumor progression of gastric cancer by binding to and regulating gastric cancer-related genes
Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by: (I) Project name: Mechanism and targeted therapy of ENO1 promoting aerobic glycolysis of gastric cancer cells by regulating PI3K/AKT/mTOR/PKM2 pathway (Grant No. 2019-0203-SFC-0015; Category: Gansu Provincial Key Research and Development Project-Social Development Category; Source: Gansu Provincial Science and Technology Department).	

		<p>(II) Project name: Mechanism of activating PKM2 through VEGF ENO1/PI3K/AKT pathway to promote aerobic glycolysis of gastric cancer cells (grant No. ZX-62000002-2021-139; Category: The Hospital Fund of Lanzhou University First Hospital; Source: Lanzhou University First Hospital). (III) The mechanism of ENO1 regulating aerobic glycolysis through PI3K/AKT/c-Fos pathway to promote the proliferation and metastasis of gastric cancer (Grant No. 20JR10RA672; Category: Gansu Science and Technology Project; Source: Gansu Provincial Science and Technology Department). (IV) Project name: Effect of ENO1 on the proliferation and metastasis of gastric cancer and its molecular mechanism (Grant No. 2020-25; Category: Young Scientific and Technological Talents Promotion Project in 2020 from Gansu Association for Science and Technology; Source: Gansu Province Science and Technology Association).</p>	
--	--	--	--

Time frame: past 36 months

2	Grants or contracts from any entity (if not indicated in item #1 above).	___ None	
3	Royalties or licenses	___ None	
4	Consulting fees	___ None	
5	Payment or honoraria for	___ None	

	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

This work was supported by: (I) Project name: Mechanism and targeted therapy of ENO1 promoting aerobic glycolysis of gastric cancer cells by regulating PI3K/AKT/mTOR/PKM2 pathway (Grant No. 2019-0203-SFC-0015; Category: Gansu Provincial Key Research and Development Project-Social Development Category; Source: Gansu Provincial Science and Technology Department). (II) Project name: Mechanism of activating PKM2 through VEGF ENO1/PI3K/AKT pathway to promote aerobic glycolysis of gastric cancer cells (grant No. ZX-62000002-2021-139; Category: The Hospital Fund of Lanzhou University First Hospital; Source: Lanzhou University First Hospital). (III) The mechanism of ENO1 regulating aerobic glycolysis through PI3K/AKT/c-Fos pathway to promote the proliferation and metastasis of gastric cancer (Grant No. 20JR10RA672; Category: Gansu Science and Technology Project; Source: Gansu Provincial Science and Technology Department). (IV) Project name: Effect of ENO1 on the proliferation and metastasis of gastric cancer and its molecular mechanism (Grant No. 2020-25; Category: Young Scientific and Technological Talents Promotion Project in 2020 from Gansu Association for Science and Technology; Source: Gansu Province Science and Technology Association). I have no other conflicts of interest to declare.

Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 2023.2.22

Your Name: Lei Yang

Manuscript Title: RNA-binding protein ENO1 promotes the glycolysis and tumor progression of gastric cancer by binding to and regulating gastric cancer-related genes

Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by: (I) Project name: Mechanism and targeted therapy of ENO1 promoting aerobic glycolysis of gastric cancer cells by regulating PI3K/AKT/mTOR/PKM2 pathway (Grant No. 2019-0203-SFC-0015; Category: Gansu Provincial Key Research and Development Project-Social Development Category; Source: Gansu Provincial Science and Technology Department).	

		<p>(II) Project name: Mechanism of activating PKM2 through VEGF ENO1/PI3K/AKT pathway to promote aerobic glycolysis of gastric cancer cells (grant No. ZX-62000002-2021-139; Category: The Hospital Fund of Lanzhou University First Hospital; Source: Lanzhou University First Hospital). (III) The mechanism of ENO1 regulating aerobic glycolysis through PI3K/AKT/c-Fos pathway to promote the proliferation and metastasis of gastric cancer (Grant No. 20JR10RA672; Category: Gansu Science and Technology Project; Source: Gansu Provincial Science and Technology Department). (IV) Project name: Effect of ENO1 on the proliferation and metastasis of gastric cancer and its molecular mechanism (Grant No. 2020-25; Category: Young Scientific and Technological Talents Promotion Project in 2020 from Gansu Association for Science and Technology; Source: Gansu Province Science and Technology Association).</p>	
--	--	--	--

Time frame: past 36 months

2	Grants or contracts from any entity (if not indicated in item #1 above).	___ None	
3	Royalties or licenses	___ None	
4	Consulting fees	___ None	
5	Payment or honoraria for	___ None	

	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

This work was supported by: (I) Project name: Mechanism and targeted therapy of ENO1 promoting aerobic glycolysis of gastric cancer cells by regulating PI3K/AKT/mTOR/PKM2 pathway (Grant No. 2019-0203-SFC-0015; Category: Gansu Provincial Key Research and Development Project-Social Development Category; Source: Gansu Provincial Science and Technology Department). (II) Project name: Mechanism of activating PKM2 through VEGF ENO1/PI3K/AKT pathway to promote aerobic glycolysis of gastric cancer cells (grant No. ZX-62000002-2021-139; Category: The Hospital Fund of Lanzhou University First Hospital; Source: Lanzhou University First Hospital). (III) The mechanism of ENO1 regulating aerobic glycolysis through PI3K/AKT/c-Fos pathway to promote the proliferation and metastasis of gastric cancer (Grant No. 20JR10RA672; Category: Gansu Science and Technology Project; Source: Gansu Provincial Science and Technology Department). (IV) Project name: Effect of ENO1 on the proliferation and metastasis of gastric cancer and its molecular mechanism (Grant No. 2020-25; Category: Young Scientific and Technological Talents Promotion Project in 2020 from Gansu Association for Science and Technology; Source: Gansu Province Science and Technology Association). I have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 2023.2.22
Your Name: Miaomiao Zeng
Manuscript Title: RNA-binding protein ENO1 promotes the glycolysis and tumor progression of gastric cancer by binding to and regulating gastric cancer-related genes
Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by: (I) Project name: Mechanism and targeted therapy of ENO1 promoting aerobic glycolysis of gastric cancer cells by regulating PI3K/AKT/mTOR/PKM2 pathway (Grant No. 2019-0203-SFC-0015; Category: Gansu Provincial Key Research and Development Project-Social Development Category; Source: Gansu Provincial Science and Technology Department).	

		<p>(II) Project name: Mechanism of activating PKM2 through VEGF ENO1/PI3K/AKT pathway to promote aerobic glycolysis of gastric cancer cells (grant No. ZX-62000002-2021-139; Category: The Hospital Fund of Lanzhou University First Hospital; Source: Lanzhou University First Hospital). (III) The mechanism of ENO1 regulating aerobic glycolysis through PI3K/AKT/c-Fos pathway to promote the proliferation and metastasis of gastric cancer (Grant No. 20JR10RA672; Category: Gansu Science and Technology Project; Source: Gansu Provincial Science and Technology Department). (IV) Project name: Effect of ENO1 on the proliferation and metastasis of gastric cancer and its molecular mechanism (Grant No. 2020-25; Category: Young Scientific and Technological Talents Promotion Project in 2020 from Gansu Association for Science and Technology; Source: Gansu Province Science and Technology Association).</p>	
--	--	--	--

Time frame: past 36 months

2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	

	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

This work was supported by: (I) Project name: Mechanism and targeted therapy of ENO1 promoting aerobic glycolysis of gastric cancer cells by regulating PI3K/AKT/mTOR/PKM2 pathway (Grant No. 2019-0203-SFC-0015; Category: Gansu Provincial Key Research and Development Project-Social Development Category; Source: Gansu Provincial Science and Technology Department). (II) Project name: Mechanism of activating PKM2 through VEGF ENO1/PI3K/AKT pathway to promote aerobic glycolysis of gastric cancer cells (grant No. ZX-62000002-2021-139; Category: The Hospital Fund of Lanzhou University First Hospital; Source: Lanzhou University First Hospital). (III) The mechanism of ENO1 regulating aerobic glycolysis through PI3K/AKT/c-Fos pathway to promote the proliferation and metastasis of gastric cancer (Grant No. 20JR10RA672; Category: Gansu Science and Technology Project; Source: Gansu Provincial Science and Technology Department). (IV) Project name: Effect of ENO1 on the proliferation and metastasis of gastric cancer and its molecular mechanism (Grant No. 2020-25; Category: Young Scientific and Technological Talents Promotion Project in 2020 from Gansu Association for Science and Technology; Source: Gansu Province Science and Technology Association). I have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 2023.2.22
Your Name: Quanlin Guan
Manuscript Title: RNA-binding protein ENO1 promotes the glycolysis and tumor progression of gastric cancer by binding to and regulating gastric cancer-related genes
Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by: (I) Project name: Mechanism and targeted therapy of ENO1 promoting aerobic glycolysis of gastric cancer cells by regulating PI3K/AKT/mTOR/PKM2 pathway (Grant No. 2019-0203-SFC-0015; Category: Gansu Provincial Key Research and Development Project-Social Development Category; Source: Gansu Provincial Science and Technology Department).	

		<p>(II) Project name: Mechanism of activating PKM2 through VEGF ENO1/PI3K/AKT pathway to promote aerobic glycolysis of gastric cancer cells (grant No. ZX-62000002-2021-139; Category: The Hospital Fund of Lanzhou University First Hospital; Source: Lanzhou University First Hospital). (III) The mechanism of ENO1 regulating aerobic glycolysis through PI3K/AKT/c-Fos pathway to promote the proliferation and metastasis of gastric cancer (Grant No. 20JR10RA672; Category: Gansu Science and Technology Project; Source: Gansu Provincial Science and Technology Department). (IV) Project name: Effect of ENO1 on the proliferation and metastasis of gastric cancer and its molecular mechanism (Grant No. 2020-25; Category: Young Scientific and Technological Talents Promotion Project in 2020 from Gansu Association for Science and Technology; Source: Gansu Province Science and Technology Association).</p>	
--	--	--	--

Time frame: past 36 months

2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	

	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

This work was supported by: (I) Project name: Mechanism and targeted therapy of ENO1 promoting aerobic glycolysis of gastric cancer cells by regulating PI3K/AKT/mTOR/PKM2 pathway (Grant No. 2019-0203-SFC-0015; Category: Gansu Provincial Key Research and Development Project-Social Development Category; Source: Gansu Provincial Science and Technology Department). (II) Project name: Mechanism of activating PKM2 through VEGF ENO1/PI3K/AKT pathway to promote aerobic glycolysis of gastric cancer cells (grant No. ZX-62000002-2021-139; Category: The Hospital Fund of Lanzhou University First Hospital; Source: Lanzhou University First Hospital). (III) The mechanism of ENO1 regulating aerobic glycolysis through PI3K/AKT/c-Fos pathway to promote the proliferation and metastasis of gastric cancer (Grant No. 20JR10RA672; Category: Gansu Science and Technology Project; Source: Gansu Provincial Science and Technology Department). (IV) Project name: Effect of ENO1 on the proliferation and metastasis of gastric cancer and its molecular mechanism (Grant No. 2020-25; Category: Young Scientific and Technological Talents Promotion Project in 2020 from Gansu Association for Science and Technology; Source: Gansu Province Science and Technology Association). I have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.